Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Skye Bioscience currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

But this is just the start. GLP-1 drugs (specifically Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Novo Nordisk plans to launch Wegovy soon ... Advt The recent launch of Mounjaro (tirzepatide), a once-weekly injectable drug for chronic weight management and type 2 diabetes by pharma giant ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Novo Nordisk has quickly expanded its discounted ... As the FDA has recently removed semaglutide and tirzepatide—the two drugs used in Wegovy and Zepbound, respectively—off its drug shortage ...